Dako has entered into a collaboration with Amgen to develop a diagnostic test for an Amgen cancer drug candidate in clinical development. “It is Dako’s mission to fight cancer. Hence, we are pleased to be chosen as Amgen’s partner once again for the development of companion diagnostics linked to Amgen’s investigational targeted therapies,” said Lars Holmkvist, Dako’s chief executive officer. “This new collaboration underlines Dako’s commitment to ...